Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia

Launched by CAIRO UNIVERSITY · Aug 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two medicines, dexamethasone and magnesium sulfate, to see which one works better when added to a local anesthetic called bupivacaine. These medicines are used during a special type of nerve block called an erector spinae plane block, which helps control pain after a planned cesarean section (C-section) performed with spinal anesthesia. The goal is to find out which medicine provides better pain relief after surgery.

Women who may join this study are between 18 and 35 years old, pregnant with a single baby at full term, and are generally healthy with no serious medical conditions. They must be scheduled for an elective (planned) C-section with spinal anesthesia. Participants will receive the nerve block with bupivacaine plus either dexamethasone or magnesium sulfate to help manage their pain after the operation. It’s important to note that women with certain health problems, allergies to these medicines, or who need emergency C-sections cannot join. This study is currently looking for participants who meet these criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age from 18 to 35 years.
• • Full-term, singleton, pregnant women.
• • American Society of Anesthesiologists (ASA) physical status II.
• • Scheduled for elective cesarean delivery under spinal anesthesia.
• Exclusion Criteria:
• • Refusal of the patient.
• • Emergency caesarean sections.
• • Patients having chronic diseases as asthma, cardiovascular disorders (Significant arrhythmias, Severe Valvular diseases, congenital heart diseases, ischemic heart disease, cardiomyopathy, deep venous thrombosis ,and pulmonary embolism)
• • Renal impairment (Creatinine level ≥ 2mg/dl, urea ≥ 25mg/dL), liver impairment \[Alanine aminotransferase (ALT) \< 45 U/L, Aspartate aminotransferase (AST) \< 45 U/L\].
• • Allergy to the drug enrolled in the study.
• • Body mass index (BMI) ≥ 35 kg/m2.
• • Hypertensive disorders of pregnancy.
• • Contraindication to spinal anesthesia, such as coagulopathy \[platelet count \<150.000, international normalized ratio (INR) \> 1.2\], or local infection.
• • Requirement for conversion to general anesthesia after spinal anesthesia will also be excluded.